Clinical trials: Macular Telangiectasia, active
Macular Telangiectasia Type 2
A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM
The overall purpose of this global, multicenter, two cohort, central image evaluator masked study is to characterize the clinical safety and efficacy of NT-501 manufactured using the Medica - Clinical Hollow Fiber Membrane…
- Trial name
- NCT06397131
- Testing
- M-CHFM, CHFM
- Where
- 6 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2 (MacTel)
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants…
- Trial name
- NCT06971939
- Testing
- NT-501/revakinagene taroretcel-lwey
- Where
- 26 sites in United States, Australia
- Volunteers
- 234 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2 (MacTel)
Study of Serine Supplementation to Protect Vision in MacTel
The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2.
- Trial name
- SEErine (NCT07342439)
- Testing
- L-serine
- Where
- 12 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- The Lowy Medical Research Institute Limited
Neurodegenerative Disorders
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases
Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription factors (1-5).
- Trial name
- NCT00874783
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization